Home » Stocks » Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. (LXRX)

Stock Price: $1.45 USD -0.03 (-1.70%)
Updated Oct 19, 2020 10:17 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 154.77M
Revenue (ttm) 320.34M
Net Income (ttm) 39.27M
Shares Out 107.11M
EPS (ttm) 0.37
PE Ratio 3.91
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $1.45
Previous Close $1.47
Change ($) -0.03
Change (%) -1.70%
Day's Open 1.49
Day's Range 1.43 - 1.50
Day's Volume 196,234
52-Week Range 1.37 - 5.33

More Stats

Market Cap 154.77M
Enterprise Value 198.17M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 107.11M
Float 103.29M
EPS (basic) 0.37
EPS (diluted) 0.37
FCF / Share 0.92
Dividend n/a
Dividend Yield n/a
Earnings Yield 25.61%
FCF Yield 63.30%
Payout Ratio n/a
Shares Short 10.13M
Short Ratio 12.22
Short % of Float 9.80%
Beta 1.37
PE Ratio 3.91
Forward PE n/a
P/FCF Ratio 1.58
PS Ratio 0.48
PB Ratio 3.69
Revenue 320.34M
Operating Income 50.44M
Net Income 39.27M
Free Cash Flow 97.98M
Net Cash -43.40M
Net Cash / Share -0.41
Gross Margin 70.84%
Operating Margin 15.75%
Profit Margin 12.30%
FCF Margin 30.58%
ROA 18.15%
ROE 1,877.21%
ROIC 13.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 1
Overweight 0
Hold 4
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

(86.85% upside)
Current: $1.45
Target: 2.70
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth409.54%-31.06%15.69%-39.04%468.89%928.53%104.04%-41.1%-62.33%-
Gross Profit31960.7289.7979.2613022.852.221.091.854.91
Operating Income141-103-129-1287.40-98.94-105-98.53-107-93.01
Net Income130-121-123-131-4.68-100-104-110-116-102
Shares Outstanding10610610510410476.3573.3069.9648.6843.26
Earnings Per Share1.16-1.14-1.17-1.27-0.05-1.31-1.42-1.61-2.38-2.38
Operating Cash Flow114-149-185-176185-75.62-91.08-94.46-87.94-82.37
Capital Expenditures-0.07-0.10-0.23-0.23-0.582.09-1.59-0.411.42-1.07
Free Cash Flow114-149-186-176184-73.53-92.67-94.87-86.52-83.44
Cash & Equivalents272160311347521339129223282211
Total Debt24524524610110310821.8823.4524.8928.48
Net Cash / Debt26.48-84.9565.12245418232107200257183
Book Value117-26.4168.27157286284170267298247
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lexicon Pharmaceuticals, Inc.
Country United States
Employees 184
CEO Lonnel Coats

Stock Information

Ticker Symbol LXRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LXRX
IPO Date April 7, 2000


Lexicon Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.